Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) regarding their holdings in American Depositary Shares (ADSs).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the transaction price of $47.617 per ADS for the reinvestment of dividends paid on October 4, 2012.
Material Changes
The filing details increases in shareholdings for specific directors and connected persons resulting from the reinvestment of dividends. There are no reported material changes to the company's operations, financial position, or strategy in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is strictly a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Key Facts for Investors to Verify
- Dividend reinvestment occurred on October 4, 2012, at a price of $47.617 per ADS.
- Directors Dr. M. M. Slaoui, Mrs. D. P. Connelly, Mr. W. C. Louv, Dr. D. Pulman, and Mr. D. E. Troy increased their holdings.
- Dr. K. Slaoui, a connected person of Dr. M. M. Slaoui, also increased holdings.
- The company was advised of these transactions on October 10, 2012.